Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety

References

• Ghoreschi K, Bruck J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011;208:2291-303
   PubMed Web of Science ®Google Scholar
• Meissner M, Valesky EM, Kippenberger S, Kaufmann R. Dimethyl fumarate - only an anti-psoriatic medication? J Dtsch Dermatol Ges 2012;10:793-801
   Google Scholar
• Schweckendiek W. [Treatment of psoriasis vulgaris]. Med Monatsschr 1959;13:103-4
   PubMedGoogle Scholar
• Loleit V, Biberacher V, Hemmer B. Current and future therapies targeting the immune system in multiple sclerosis. Curr Pharm Biotechnol 2014;15(3):276-96
   PubMed Web of Science ®Google Scholar
• FDA approves new multiple sclerosis treatment: Tecfidera. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345528.htm [Accessed 28 March 2013]
   Google Scholar
• Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol 2011;10:1026-34
   PubMed Web of Science ®Google Scholar
• Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 1992;31:333-6
   PubMed Web of Science ®Google Scholar
• Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-35
   PubMed Web of Science ®Google Scholar
• Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology 2007;68:326-37
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52
   PubMed Web of Science ®Google Scholar
• Barcellos LF, Oksenberg JR, Begovich AB, et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003;72:710-16
   PubMed Web of Science ®Google Scholar
• Gocke AR, Cravens PD, Ben LH, et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 2007;178:1341-8
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Sad S. The expanding universe of T-cell subsets: th1, Th2 and more. Immunol Today 1996;17:138-46
   PubMedGoogle Scholar
• Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:43-72
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002;3:944-50
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod’homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43
   PubMed Web of Science ®Google Scholar
• Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci 2012;13:11783-803
   PubMed Web of Science ®Google Scholar
• Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol 2014;262(Pt A):52-6
   PubMedGoogle Scholar
• Lin SX, Lisi L, Dello RC, et al. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011;3
   Google Scholar
• Hollins DL, Suliman HB, Piantadosi CA, Carraway MS. Glutathione regulates susceptibility to oxidant-induced mitochondrial DNA damage in human lymphocytes. Free Radic Biol Med 2006;40:1220-6
   PubMed Web of Science ®Google Scholar
• Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-8
   PubMed Web of Science ®Google Scholar
• Bureau F, Vanderplasschen A, Jaspar F, et al. Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. Blood 2002;99:3683-91
   PubMed Web of Science ®Google Scholar
• Ghods AJ, Glick R, Braun D, Feinstein D. Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas. Surg Neurol Int 2013;4:160
   PubMedGoogle Scholar
• Odom RY, Dansby MY, Rollins-Hairston AM, et al. Phytochemical induction of cell cycle arrest by glutathione oxidation and reversal by N-acetylcysteine in human colon carcinoma cells. Nutr Cancer 2009;61:332-9
   PubMed Web of Science ®Google Scholar
• Loewe R, Valero T, Kremling S, et al. Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res 2006;66:11888-96
   PubMed Web of Science ®Google Scholar
• Milligan SA, Nopajaroonsri C. Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res 2001;21:39-44
   PubMed Web of Science ®Google Scholar
• Wang CY, Cusack JCJr, Liu R, Baldwin ASJr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-17
   PubMed Web of Science ®Google Scholar
• Meissner M, Doll M, Hrgovic I, et al. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol 2011;131:1356-64
   PubMed Web of Science ®Google Scholar
• di Nuzzo L, Orlando R, Nasca C, Nicoletti F. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther 2014;8:555-68
   PubMed Web of Science ®Google Scholar
• Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 2012;287:28017-26
   PubMed Web of Science ®Google Scholar
• Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006;145:101-7
   PubMed Web of Science ®Google Scholar
• de Jong R, Bezemer AC, Zomerdijk TP, et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996;26:2067-74
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Mrowietz U, Rocken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med (Berl) 2003;81:471-80
   PubMed Web of Science ®Google Scholar
• Loewe R, Pillinger M, de Martin R, et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol 2001;117:1363-8
   PubMed Web of Science ®Google Scholar
• Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002;168:4781-7
   PubMed Web of Science ®Google Scholar
• Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341:274-84
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-92
   PubMed Web of Science ®Google Scholar
• Kapturczak MH, Wasserfall C, Brusko T, et al. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol 2004;165:1045-53
   PubMed Web of Science ®Google Scholar
• Albrecht P, Lewerenz J, Dittmer S, et al. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets 2010;9:373-82
   PubMed Web of Science ®Google Scholar
• Frohman EM, Racke MK, Raine CS. Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 2006;354:942-55
   PubMed Web of Science ®Google Scholar
• Nicholas JA, Boster AL, Imitola J, et al. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Des Devel Ther 2014;8:897-908
   Web of Science ®Google Scholar
• Venci JV, Gandhi MA. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 2013;47:1697-702
   PubMed Web of Science ®Google Scholar
• Sheikh SI, Nestorov I, Russell H, et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers. Clin Ther 2013;35:1582-94
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463-72
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Havrdova E, Hutchinson M, Kurukulasuriya NC, et al. Oral BG-12 (dimethyl fumarate. for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97. Expert Opin Pharmacother 2013;14:2145-56
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999;141:424-9
   PubMed Web of Science ®Google Scholar
• Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149:363-9
   PubMed Web of Science ®Google Scholar
• Russell H, O’Gorman J, Li J, et al. BG-12 (Dimethyl Fumarate) with aspirin pretreatment or slow dose titration. [Accessed 30 May 2014]
   Google Scholar
• Phillips JT, Erwin A, Agrella S, et al. A Delphi panel to address management of gastrointestinal side effects observed with use of delayed-release dimethyl fumarate. [Accessed 29 May 2014]
   Google Scholar
• Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-8
   PubMed Web of Science ®Google Scholar
• Sweetser MT, Dawson KT, Bozic C. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013;369:1082
   Google Scholar
• van Oosten BW, Killestein J, Wattjes MP. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013;369:1081-2
   Google Scholar
• Sweetser MT, Dawson KT, Bozic C. Manufacturer’s response to case reports of PML. N Engl J Med 2013;368:1659-61
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012;64:3043-51
   PubMed Web of Science ®Google Scholar
• MS Trust. PML case reported for dimethyl fumarate (Tecfidera). Available from: http://www.mstrust.org.uk/news/article.jsp?id=6542 [Accessed 23 October 2014]
   Google Scholar
• Tirrell M. Biogen Boosts 2013 Forecast as Tecfidera Tops Estimates. Available from:http://www.bloomberg.com/news/articles/2013-10-28/biogen-boosts-2013-forecast-as-tecfidera-tops-estimates [Accessed 28 October 2013]
   Google Scholar